Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;13(1):64-69.
doi: 10.15420/ecr.2017:17:2.

Cardio-oncology: A Focus on Cardiotoxicity

Athanasios Koutsoukis  1 , Argyrios Ntalianis  1 , Evangelos Repasos  1 , Efsthathios Kastritis  1 , Meletios-Athanasios Dimopoulos  1 , Ioannis Paraskevaidis  1
Affiliations
Review

Cardio-oncology: A Focus on Cardiotoxicity

Athanasios Koutsoukis et al. Eur Cardiol. 2018 Aug.

Abstract

Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors. Cancer survival rates have been constantly increasing, mainly because of the advent of new, more potent and targeted therapies. However, many of the new therapies - along with some of the older chemotherapeutic regimens such as anthracyclines - are potentially cardiotoxic, which is reflected increasingly frequently in the published literature. Cardiotoxicity adversely affects prognosis in cancer patients, thus its prevention and treatment are crucial to improve quality and standards of care. This review aims to explore the existing literature relating to chemotherapy- and radiotherapy-induced cardiotoxicity. An overview of the imaging modalities for the identification of cardiotoxicity and therapies for its prevention and management is also provided.

Keywords: Adverse effects; cancer; cardio-oncology; chemotherapy; chemotherapy-associated cardiotoxicity.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare. AK and AN contributed equally to this work.

Figures

Figure 1:
Figure 1:. Proposed Algorithm for the Baseline Evaluation of a Patient Planned to Receive Cardiotoxic Treatment
Figure 2:
Figure 2:. Proposed Follow-up AlgorithmA for Patients Receiving Anthracyclines
Figure 3:
Figure 3:. Proposed Follow-up Algorithm for Patients Receiving Trastuzumab
See this image and copyright information in PMC

References

    1. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7. doi: 10.7326/0003-4819-91-5-710. - DOI - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2009;53:2231–47. doi: 10.1016/j.jacc.2009.02.050. - DOI - PubMed
    1. Clark RA, Berry NM, Chowdhury MH et al. Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis. Intern Med J. 2016;46:1297–306. doi: 10.1111/imj.13201. - DOI - PubMed
    1. Raschi E, De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med. 2012;7:113–31. doi: 10.1007/s11739-011-0744. - DOI - PubMed

LinkOut - more resources